NCT02217709View on ClinicalTrials.gov

Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 8, 2014

Primary Completion Date

June 29, 2020

Study Completion Date

June 29, 2020

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate Cancer
Interventions
DRUG

phenelzine sulfate

Given by mouth

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

questionnaire administration

Ancillary studies

Trial Locations (4)

90033

Los Angeles County-USC Medical Center, Los Angeles

USC Norris Comprehensive Cancer Center, Los Angeles

90211

USC Norris Westside Cancer Center, Beverly Hills

91105

Keck Medical Center of USC Pasadena, Pasadena

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT02217709 - Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter